Newsroom

Recent News Releases

November 22, 2019 2019-11-22

TAKHZYRO® (lanadelumab injection) receives positive recommendation from CADTH’s Canadian Drug Expert Committee (CDEC) for the routine prevention of hereditary angioedema (HAE) attacks
July 10, 2019 2019-07-10 Health Canada has authorized VYVANSE® (lisdexamfetamine dimesylate), the first and only, chewable tablet for the treatment of attention deficit/hyperactivity disorder (ADHD)1
June 13, 2019 2019-06-13 Pedalling in support of rare disease research
March 11, 2019 2019-03-11 Takeda Canada announces positive results for ENTYVIO® (vedolizumab) vs. Humira® (adalimumab) in first IBD study to compare biological agents head-to-head
March 1, 2019 2019-03-01 One in 12 Canadians are affected by a rare disease. Are you one of them?  Takeda Canada commemorates Rare Disease Day with the launch of video patient stories
Copyright 1995-2018 Takeda Pharmaceutical Company Limited. All rights reserved.

You are about to leave the Takeda Canada website. This link is provided by Takeda as a resource to website visitors. Takeda Canada does not endorse or take responsibility for information presented on any website except its own.

Do you wish to leave this site?